Publications by the researcher in collaboration with Isabel Lastres Becker (13)

2005

  1. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

    Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206

  2. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

    Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107

2004

  1. Involvement of the endocannabinoid system in motor disorders

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182

  2. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

2002

  1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Synapse, Vol. 44, Núm. 1, pp. 23-35

  2. Endocannabinoids and basal ganglia functionality

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267

  3. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease

    Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608

  4. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease

    Brain Research, Vol. 929, Núm. 2, pp. 236-242

  5. The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects

    Pharmacology and Therapeutics, Vol. 95, Núm. 2, pp. 137-152

2001

  1. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

    NeuroReport, Vol. 12, Núm. 10, pp. 2125-2129

  2. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors

    Journal of Medicinal Chemistry, Vol. 44, Núm. 26, pp. 4505-4508

  3. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

    European Journal of Neuroscience, Vol. 14, Núm. 11, pp. 1827-1832

1999

  1. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide

    Life Sciences, Vol. 65, Núm. 3, pp. 327-336